Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ATG-022 Compared With Investigator's Choice of Treatment in Subjects With Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07795346 is registered in ClinicalTrials.gov with Antengene Biologics Limited as lead sponsor.

NCT NCT07795346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07795346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ATG-022 Compared With Investigator's Choice of Treatment in Subjects With Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Antengene Biologics Limited
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 31, 2029
Enrollment
380 (estimated)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction adenocarcinoma